John Childs Sells 100,000 Shares of Veradermics (NYSE:MANE) Stock

Key Points

• Director John Childs sold 100,000 Veradermics shares at an average price of $107.12, generating $10.7 million. His remaining stake fell 34% to 194,117 shares.
• Veradermics shares recently traded at $113.18, with a market capitalization of approximately $4.73 billion and a 52-week range of $32.00 to $131.24.
• The company met quarterly loss expectations at $0.58 per share, while analysts maintain a “Moderate Buy” consensus and an average price target of $153.00.

Veradermics, Incorporated (NYSE:MANE - Get Free Report) Director John Childs sold 100,000 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $107.12, for a total value of $10,712,000.00. Following the completion of the transaction, the director owned 194,117 shares in the company, valued at approximately $20,793,813.04. This represents a 34.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Veradermics Stock Performance

MANE stock traded up $2.18 during midday trading on Friday, reaching $113.18. 523,366 shares of the company's stock traded hands, compared to its average volume of 601,161. The firm has a fifty day simple moving average of $109.45. Veradermics, Incorporated has a 52 week low of $32.00 and a 52 week high of $131.24. The firm has a market capitalization of $4.73 billion and a P/E ratio of -85.74.

Veradermics (NYSE:MANE - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.58) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.58). On average, equities research analysts anticipate that Veradermics, Incorporated will post -2.78 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the company. B. Riley Financial started coverage on Veradermics in a research note on Wednesday, July 15th. They issued a "buy" rating and a $170.00 price objective for the company. Weiss Ratings initiated coverage on Veradermics in a report on Tuesday, May 26th. They set a "sell (d+)" rating for the company. Wall Street Zen upgraded Veradermics from a "sell" rating to a "hold" rating in a research note on Saturday, August 1st. Citigroup lifted their price objective on shares of Veradermics from $135.00 to $160.00 and gave the stock a "buy" rating in a report on Thursday, July 16th. Finally, Leerink Partners upped their target price on shares of Veradermics from $75.00 to $90.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 22nd. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $153.00.

About Veradermics

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source